Arkhipov Alexander

2.8k citations
4 papers · 629 indexed · 1 hit paper · h-index 3

Arkhipov Alexander

4 papers receiving 618 citations

Hit Papers

Pembrolizumab for Persistent, Recurrent, or Metastatic Ce...5812021202620222024100200300400500

Peers

Arkhipov Alexander
Comparison fields: 5 of 49
  • Obstetrics and Gynecology 295
  • Reproductive Medicine 115
  • Oncology 352
  • Epidemiology 185
  • Immunology 94
Replace Sarper Toker with:
Sarper Toker United States
M. Valeria Cáceres Argentina
Mivael Olivera Peru
Liju Zong China
Steven DeCesare United States
Juan Carlos Alcedo United Kingdom
Damiano Arciuolo Italy
Cyril Abdeddaim France
Shinichi Togami Japan
Robert Orlowski United States
Arkhipov Alexander relative to Sarper Toker United States Sarper Toker's profile →
Citations per field
00.5×1.5×
Sarper Toker · 1×
Citations per year

Countries citing papers authored by Arkhipov Alexander

Since Specialization
Citations

This map shows the geographic impact of Arkhipov Alexander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arkhipov Alexander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arkhipov Alexander more than expected).

Fields of papers citing papers by Arkhipov Alexander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arkhipov Alexander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arkhipov Alexander. The network helps show where Arkhipov Alexander may publish in the future.

Co-authorship network

The 19 scholars most cited alongside Arkhipov Alexander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Arkhipov Alexander Line = papers co-authored together Arkhipov Alexander links everyone, so they are left out of the graph.

All Works

4 of 4 papers shown
#Work
1 202337
2 202210
3
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancerbreakdown →
2021581
4 20211

About Arkhipov Alexander

Arkhipov Alexander is a scholar working on Obstetrics and Gynecology, Surfaces, Coatings and Films and Oncology, having authored 4 papers that have together received 629 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (3 papers), Endometrial and Cervical Cancer Treatments (3 papers), Colorectal and Anal Carcinomas (2 papers), Plasma Diagnostics and Applications (1 paper), nanoparticles nucleation surface interactions (1 paper) and Electron and X-Ray Spectroscopy Techniques (1 paper). The work is most often cited by research in Obstetrics and Gynecology (295 citations), Reproductive Medicine (115 citations) and Oncology (352 citations). Arkhipov Alexander has collaborated with scholars based in Russia, Italy and Chile. Frequent co-authors include M. Valeria Cáceres, Ronnie Shapira‐Frommer, Vincent Castonguay, Coraline Dubot, Kan Li, Domenica Lorusso, Pamela Salman, Vanessa Samouëlian, Krishnansu S. Tewari and Mahmut Gümüş. Their work appears in journals such as Obstetrical & Gynecological Survey, New England Journal of Medicine, The Lancet Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026